Agenus’ lead cancer vaccine flops, investigators read last rites over glioblastoma PhII
Just days after handing over the reins on a big antibody collaboration to Incyte, Agenus is now slamming the brakes on its top cancer vaccine trial, conceding a flop.
The Lexington, MA-based biotech $AGEN says an independent data monitoring committee overseeing the Phase II combination study of its cancer vaccine Prophage with Avastin (bevacizumab) found no encouragement that the vaccine — made of heat shock protein-peptide complexes taken from a patient’s tumor tissue — was any better than bevacizumab alone in prolonging survival among brain cancer patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.